NKA Bio, Inc.
Baltimore, MD
- UEI
- F6TLH1UTJG53
- CAGE
- 9LEW0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- Schapiro Bldg, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
- Website
- nkabio.com
- Founded
- 2023
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $74,464 |
| FY2025 | $1,245,837 |
| FY2024 | $72,672 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Air Force | $74,464 |
Contract awards
Similar vendors
About the company
NKA Bio, Inc., a self-certified small disadvantaged business based in Baltimore, Maryland, delivers combat casualty care medical countermeasures and inhalable therapeutics to the Air Force Research Laboratory as a prime contractor under Total Small Business set-asides. The company operates exclusively as a prime on federal R&D awards, with three purchase orders and an SBIR Phase I contract concentrated wholly within the Department of the Air Force Materiel Command Research Laboratory.
NKA Bio's capability portfolio centers on injectable and inhalable treatments for acute trauma and shock in military field medicine. The vendor's representative work includes a $1.25 million Total Small Business purchase order from AFRL for anti-shock injection technology to improve combat casualty care (ultimate completion January 15, 2027), a $74,464 Total Small Business purchase order for inhalable treatment to restore lung function after acute lung injury (awarded July 15, 2026, completing October 15, 2026), and a $72,672 SBIR Phase I award for anti-shock toxin antibody drug development for combat casualty care (completed December 17, 2024). All performance occurs in Arlington, Maryland.
Customer concentration is absolute — AFRL represents 100% of both awards by count and combined potential value at $1.4 million. The vendor has no presence on agency-wide vehicles, GWACs, or BPAs; all three awards are direct purchase orders and research contracts. Combined obligated dollars equal combined potential value at $1.4 million, indicating full funding. One award valued at $1.2 million faces ultimate completion within the next twenty-four months and therefore presents recompete exposure. NKA Bio operates solely as a prime contractor with no subcontract footprint in the source data. The company competes under the Total Small Business set-aside across all three awards, with recent activity showing one award per calendar year from 2024 through 2026.
Quick answers
Is NKA Bio, Inc. registered in SAM.gov?
NKA Bio, Inc.'s SAM.gov registration expired on June 29, 2026.
How much has NKA Bio, Inc. received in federal contracts?
Federal contracts obligated $1,245,837 to NKA Bio, Inc. in fiscal year 2025 and $1,392,973 in fiscal years 2023 through 2027.
What is NKA Bio, Inc.'s most recent federal award?
NKA Bio, Inc.'s most recent federal contract award is Inhalable treatment to restore lung function after acute lung injury (FA864926P0080), from Air Force Research Laboratory (AFMC), on July 15, 2026.
On GovTribe
See NKA Bio, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors